# Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

> **NCT03902691** · PHASE3 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 372 (actual)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Pegol-Sihematide
- **DRUG:** ESPO

## Key facts

- **NCT ID:** NCT03902691
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2021-02-28
- **Final completion:** 2022-05-30
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03902691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03902691, "Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03902691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*